右佐匹克隆的临床研究现状

doi:10.12092/j.issn.1009-2501.2019.11.014

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (11): 1300-1304.doi: 10.12092/j.issn.1009-2501.2019.11.014

右佐匹克隆的临床研究现状

贾敏¹，黄金莎²，刘群会¹，王涛²

¹恩施土家族苗族自治州中心医院，恩施 445000，湖北；²华中科技大学同济医学院附属协和医院，武汉 430022，湖北

收稿日期:2019-09-09 修回日期:2019-10-07 出版日期:2019-11-26 发布日期:2019-12-02
通讯作者: 王涛，男，博士研究生，博士生导师，主任医师，研究方向：帕金森病及睡眠障碍。 Tel：027-85726668 E-mail：wangtaowh@hust.edu.cn
作者简介:贾敏，女，硕士研究生，主治医师，研究方向：帕金森病及运动障碍性疾病。 Tel：15997766372 E-mail：jiamin19830108@sina.com
基金资助:
国家重点研发计划（2017YFC1310200）；国家自然科学基金（81671260，81974201）

Clinical research status of eszopiclone

JIA Min¹, HUANG Jinsha², LIU Qunhui ¹, WANG Tao²

¹ Department of Neurology, the Central Hospital of Enshi Tujia and Miao Autonomous Prefectures, Enshi 445000, Hubei, China; ² Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China

Received:2019-09-09 Revised:2019-10-07 Online:2019-11-26 Published:2019-12-02

摘要/Abstract

摘要：

右佐匹克隆是一种非苯二氮卓类镇静催眠药，通过异构性调控GABA受体发挥镇静催眠作用，是佐匹克隆的S异构体，但对中枢苯二氮卓类受体的亲和性比佐匹克隆强50倍，不良反应和毒性更小。右佐匹克隆于2004年获得美国FDA批准用于治疗睡眠障碍。近年来，随着临床应用的普及，相关的临床研究数据也在不断更新，临床上发现其不仅可用于治疗原发性失眠，还可用于呼吸睡眠暂停、抑郁症、创伤后应激障碍、围绝经期等伴随的共病性失眠。因此，本文就右佐匹克隆近十余年来的临床研究进展进行综述。

关键词: 右佐匹克隆, 镇静催眠, 失眠

Abstract:

Eszopiclone is a non-benzodiazepine sedative and hypnotic agent, which plays a sedative and hypnotic effects by regulating GABA receptor through isomerism, with the affinity to the central benzodiazepine receptor in about 50 times stronger than zopiclone, with less adverse reaction and toxicity. Eszopiclone has been approved by Food and Drug Administration (FDA) of United States for the treatment of insomnia in 2004. In recent years, with the popularization of clinical application, relevant clinical research data are constantly updated. In clinical practice, it could be used not only for primary insomnia, but also for the comorbid insomnia accompanied by sleep apnea syndrome, depression, post-traumatic stress disorder, perimenopausal and postmenopausal women. It is worthy to take a brief review on the clinical literatures of eszopiclone in order to provide a updated introduction for the clinicians.

Key words: eszopiclone, sedative hypnotics, insomnia

中图分类号:

R971+.3

贾敏，黄金莎，刘群会，王涛. 右佐匹克隆的临床研究现状[J]. 中国临床药理学与治疗学, 2019, 24(11): 1300-1304.

JIA Min, HUANG Jinsha, LIU Qunhui, WANG Tao. Clinical research status of eszopiclone[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1300-1304.

参考文献

［1］Monti JM，Pandi-Perumal SR. Eszopiclone: its use in the treatment of insomnia［J］. Neuropsychiatr Dis Treat，2007, 3: 441-453.
［2］Wilson S, Anderson K, Baldwin D,et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update［J］. Psychopharmacolog，2019,33（8）:923-947.
［3］Huedo-Medina TB，Kirsch I，Middlemass J，et al． Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration［J］． Brit Med J，2012,345: e8343.
［4］Pinto LR Jr, Bittencourt LR, Treptow EC, et al. Eszopiclone versus zopiclone in the treatment of insomnia［J］. Clinics, 2016,71(1): 5-9.
［5］Smith PR，Sheikh KL，Costan-Toth C，et al． Eszopiclone and zolpidem do not afect the prevalence of the low arousal threshold phenotype［J］．J Clin Sleep Med，2017, 13: 115-119.
［6］Matheson E,Hainer BL.Insomnia: pharmacologic therapy［J］.Am Fam Physician,2017,96(1):29-35.
［7］Dixon CL，Harrison NL，Lynch JW，et al. Zolpidem and eszopiclone prime alpha1beta2gamma2 GABAA receptors for longer duration of activity［J］． Brit J Pharmacol，2015, 172: 3522-3536.
［8］Tariq SH，Pulisetty S．Pharmacotherapy for insomnia［J］．Clin Geriatr Med, 2008, 24(1): 93-105．
［9］Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia［J］. Clin Ther, 2006, 28(4): 491-516.
［10］Schroeck JL, Ford J, Conway EL, et al. Review of safety and efficacy of sleep medicines in older adults［J］. Clin Ther, 2016, 38(11):2340-2372.
［11］Wu F,Zhao XL,Wei MJ,et al.Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers［J］.Arzneimittelforschunq,2012,62(12):561-565.
［12］Halas CJ. Cost-effectiveness of eszopiclone for treatment of chronic insomnia［J］. Expert Rev Pharmacoecon Outcomes Res, 2007, 7(1): 9-17.
［13］Abad VC, Guilleminault C. Insomnia in elderly patients: Recommendations for pharmacological management［J］． Drugs Aging, 2018, 35(9): 791-817.
［14］Liang L,Huang Y,Xu R,et al.Eszopiclone for the treatment of primary insomnia:a systematic review and meta-analysis of double-blind,randomized,placebo-controlled trials［J］.Sleep Medicine,2019,62:6-13.
［15］Roth T，Walsh JK，Krystal A，et al． An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia［J］． Sleep Med，2005, 6: 487-495.
［16］Botteman MF，Ozminkowski RJ，Wang S，et al． Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model［J］． CNS Drugs，2007, 21: 319-334.
［17］Uchimura N，Kamijo A，Takase T． Effects of eszopiclone on safety，subjective measures of efficacy，and quality of life in elderly and nonelderly Japanese patients with chronic insomnia，both with and without comorbid psychiatric disorders: a 24-week，randomized，double-blind study［J］．Ann Gen Psychiatry, 2012, 11(1): 15. doi: 10.1186/1744-859X-11-15.
［18］Rsner S, Englbrecht C, Wehrle R, et al. Eszopiclone for insomnia［J］. Cochrane Database Syst Rev.2018; 10:CD010703. doi:10.1002/14651858.CD010703.pub2.
［19］Lettieri CJ, Quast TN, Eliasson AH, et al. Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial［J］. Sleep, 2008, 31(9): 1310-1316.
［20］Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea［J］. Cochrane Database Syst Rev, 2015, (7): CD011090. doi: 10.1002/14651858.CD011090.pub2.
［21］Eckert DJ, Owens RL, Kehimann GB, et al. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold［J］. Clinical Science, 2011, 120(12): 505-514.
［22］Mason M, Welsh EJ, Smith I. Drug therapy for obstructive sleep apnoea in adults［J］. Cochrane Database Systematic Reviews, 2013,31(5): CD003002.
［23］Edwards BA, Sands SA, Owens RL. et al. The combination of supplemental oxygen and a hypnotic markedly improves obstructive sleep apnea in patients with a mild to moderate upper airway collapsibility［J］. Sleep, 2016, 39(11): 1973-1983.
［24］Kishi T,Matsunaga S,Iwata N.Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder:a systematic review and mata-analysis of randomized controlled trials［J］.Eur Arch Psychiatry Clin Neurosci,2017,267(2):149-161.
［25］Pollack MH，Hoge EA，Worthington JJ，et al．Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized，double-blind，placebo-controlled trial［J］．J Clin Psychiat, 2011; 72: 892-897.
［26］Soares CN,Joffe H,Rubens R,et al.Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial ［J］.Obstetricians Gynecology,2006,108(6):1402-1410.
［27］Joffe H, Petrillo L, Viquera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial［J］. Am J Obsretrics Gynecol, 2010, 202(2): 171.e1-e11.
［28］Menza M， Dobkin RD， Marin H， et al． Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo［J］．Movement Disorders, 2010, 25(11): 1708-1714.
［29］Trotti LM, Bliwise DL. Treatment of the sleep disorders associated with Parkinson's disease［J］. Neurotherapeutics, 2014, 11(1): 68-77.
［30］Olireira P, Coroa M, Madeira N. Treatment options for insomnia in schizophrenia: A systematic review［J］. Pharmacopsychiatry, 2019, 52(4): 165-169.
［31］李亚玲, 叶建飞, 李婷,等. 右佐匹克隆合并艾司西酞普兰治疗广泛性焦虑伴失眠的对照研究［J］. 中国临床药理学与治疗学, 2014, 19（1）：54-57.
［32］Roth T, Price JM, Amato DA, et al. The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study［J］. Prim Care Companion J Clin Psychiatry, 2009,11(6): 292-301.
［33］Yao L, Ramirez AD, Roecker AJ, et al. The dual orexin receptor antagonist, DoRA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine［J］. J Neurochem, 2017, 142(2): 204-214.
［34］Guzowski JF, McNaughton BL, Barnes CA, et al. Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles ［J］. Nat Neurosci, 1999, 2(12):1120-1124.
［35］Uslaner JM, Tye SJ, Eddins DM, et al. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition［J］. Sci Transl Med, 2013, 5(179): 179ra44.
［36］Hair PI, McCormack PL, Curran MP. Eszopiclone:a review of its use in the treatment of insomnia［J］. Drugs, 2008,68: 1415-1434.
［37］Halas CJ. Eszopicolne ［J］.Am J Health Syst Pharm, 2006, 63: 41-48.
［38］Treves N, Perlmman A, Kolenberg Geron L, et al. Z-drugs and risk for falls and fractures in older adults-a systemayic review and meta-analysis［J］. Age Ageing, 2018, 47(2): 201-208.

[1]	赵正卿, 李雁鹏, 向小霞, 庄建华, 赵忠新. 慢性失眠的发病机制与认知行为治疗[J]. 中国临床药理学与治疗学, 2021, 26(5): 482-486.
[2]	李雁鹏, 赵正卿, 王雯雯, 庄建华, 赵忠新. 慢性失眠临床诊断与药物治疗研究现状[J]. 中国临床药理学与治疗学, 2021, 26(5): 487-490.
[3]	蔡丹丹, 桂冬辉, 张建兵, 周文华. 小剂量利培酮联合曲唑酮应用于海洛因成瘾脱毒期的疗效分析[J]. 中国临床药理学与治疗学, 2019, 24(1): 94-98.
[4]	李亚玲, 叶建飞, 李婷, 李国荣. 右佐匹克隆合并艾司西肽普兰治疗广泛性焦虑伴失眠的对照研究[J]. 中国临床药理学与治疗学, 2014, 19(1): 54-57.
[5]	李涛. 失眠症中药新药临床试验疗效评价的几个问题探讨[J]. 中国临床药理学与治疗学, 2006, 11(4): 375-378.
[6]	高蕊, 郑青山, 黄继汉, 李涛, 孙瑞元. 疏可眠胶囊治疗失眠症(肝气郁结证)有效性和安全性的临床研究[J]. 中国临床药理学与治疗学, 2004, 9(6): 653-657.

右佐匹克隆的临床研究现状

Clinical research status of eszopiclone

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价